ALK4 and ALK5 (TGFβRI) inhibitor
Galunisertib is an ALK4 and ALK5 (TGFβRI) inhibitor (IC50 values are 77.7 and 172 nM, respectively). Also inhibits a range of other kinases with submicromolar IC50s including MINK, TGFβRII, ALK6 and ACVR2B. Inhibits TGFβ-induced SMAD phosphorylation in cancer cell lines
in vitro
in vivo
. Also reverses TGFβ-mediated suppression of T cell proliferation. Prevents TGFβ-mediated EMT and cell migration
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-125727 |
| Réf. fabricant | 18779136 |
| Nom chimique ou matériau | 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4 H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide |
| CAS | 700874-72-2 |
| Quantité | 25 mg |
| Cible | TGF-beta Receptor Inhibitors |
| Formule moléculaire | C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O |
| Poids de la formule | 369.43 |
| Type de produit | Inhibitor |
| Pureté | 98% |
